Food for Thought: The Ketogenic Diet and Neurological Diseases


Tarrytown House Estate on the Hudson
49 East Sunnyside Lane.
Tarrytown, NY 10591
(800) 553-8118 or (914) 591-8200


Thursday, November 2, 2017
Date & Time Event
6:00PM-7:00PM Welcome Reception, Library/Sunporch
7:00PM-9:00PM Dinner, Library/Sunporch
Friday, November 3, 2017
Date & Time Event
7:30AM-8:45AM Breakfast in the Mansion
  Symposium Events, Henry Hudson Room
8:50AM-10:45AM Session 1: Ketogenesis in Context
Chair: Suzana Herculano Houzel
  8:50-9:20 Kevin Behar - General physiological effects of ketogenesis: The effects of ketogenesis on human physiology. Ketone metabolism in the human brain; knowns and unknowns. Summary of brain ketone metabolism in studies of subjects without brain diseases. Species and developmental age differences. What neurological functions can and cannot be supported by ketones?
  9:20-9:35 Questions & Discussion
  9:35-10:05 Adam Hartman - Identifying the key metabolic characteristics of ketogenic diets: Ketogenesis? Calorie restriction? Energy restriction? Anti-inflammation? Something else? All these and more?
  10:05-10:20 Questions & Discussion
  10:20-10:45 General Discussion
10:45AM-11:00AM Break
11:05AM-1:05PM Session 2: Ketogenic diets and epilepsy
Chair: Hannah Landecker
  11:05-11:35 Susan Masino - Historical overview of the use of Ketogenic diets in pediatric epilepsy and the proposed mechanisms for its clinical effectiveness.
  11:35-11:50 Questions & Discussion
  11:50-12:20 Jong Rho - Learning from failures: When ketogenic diets are ineffective in epilepsy or other seizure disorders do we know why? What have we learned from other neurological disorder case studies? What characterizes the key components of the KD required for clinical efficacy in different patient groups?
  12:20-12:35 Questions & Discussion
  12:35-1:00 General Discussion
1:15PM-2:45PM Lunch in the Mansion
2:50PM-4:50PM Session 3: Ketogenic diets in neurological diseases other than epilepsy – what’s the rationale?
  The focus for this session will be on neurodegenerative disease and brain tumor – two case studies that should generalize to other neurological disorders. The important questions include: What is the rationale for thinking the KD would be effective in neurodegenerative disorders? The KD has been considered for Alzheimer’s, Parkinson’s, and ALS. How useful will it be in diseases where cell loss is a major component of the pathophysiology? There is some evidence that the KD can be effective in brain tumor patients – what mechanistic knowledge is available? Where do we have data from humans? Is possible to learn anything from individuals self-initiating the diet as a treatment?
Chair: Peter Canoll
  2:50-3:10 Discussant 1: Karin Borges
  3:10-3:30 Discussant 2: Adrienne Scheck
  3:30-4:50 Group Discussion
6:00PM-7:00PM Reception
7:00PM-9:00PM Dinner in the Mansion

Saturday, November 4, 2017
Date & Time Event
7:30AM-8:45AM Breakfast in the Mansion
  Workshop, Henry Hudson Room
8:50AM-10:45AM Session 4: Ketogenic diets – opportunities for mechanistic studies in human patients

The interest in using the KD clinically is high. This presents the opportunity to prospectively design optimal clinical studies. What would be the right patient group to target? Ideally, what data should be acquired? What is the best use of existing and emerging technologies?

Ideas that might be tested: Can the brain adapt (or develop resistance?) to chronic use of KD? Does intermittent non-compliance contribute to failure or could intermittence be useful if constrained by mechanism?

Chair: John Laterra
Discussant 1: Eric Kossoff
  9:10-9:30 Discussant 2: Srishti Nangia
  9:30-10:45 Group Discussion
10:45AM-11:05AM Break
11:05AM-1:05PM Final Session
  Recommendations for progress based on cumulative suggestions made during the workshop.
Chair: Susan Fitzpatrick
  11:05-11:20 Presenter 1: Henk de Feyter
  11:20-11:35 Presenter 2: Farah Lubin
  11:35-1:05 Group Discussion & Recommendations
1:15PM-2:45PM Lunch in the Mansion & Departures